Risk of Ovarian Cancer in Patients With a Pelvic Mass
NCT00315692 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 566
Last updated 2011-11-08
Summary
The purpose of this clinical trial is to evaluate the ability of multiple serum biomarkers to estimate the risk of ovarian cancer in women presenting with pelvic mass (defined as a simple, complex or a solid ovarian cyst / pelvic mass).
Conditions
Interventions
- DEVICE
-
Biomarker Assay (CA125 and HE4)
Sponsors & Collaborators
-
Fujirebio Diagnostics, Inc.
lead INDUSTRY
Principal Investigators
-
Richard Moore, M.D. · Womens and Infant's Hosapital of Rhode Island
Eligibility
- Min Age
- 18 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-12-31
- Completion
- 2007-02-28
Countries
- United States
Study Locations
More Related Trials
-
Biomarkers for Early Detection of Ovarian Cancer Using Uterine Lavage
NCT03150121 ·Status: UNKNOWN ·Phase: NA
-
Removal of the Ovaries/Fallopian Tubes and CA-125 Screening to Reduce the Risk of Ovarian Cancer in Women at Increased Genetic Risk
NCT00043472 ·Status: COMPLETED
-
Predictors of Relapse of Ovarian, Peritoneal, and Fallopian Tube Cancers
NCT00086567 ·Status: COMPLETED
-
Study Looking at Biomarkers in Ovarian Cancer
NCT03419689 ·Status: RECRUITING ·Phase: NA
-
Primary Tumor Harvest for the Purpose of Possible Use in a Future Clinical Trial in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT00801320 ·Status: COMPLETED ·Phase: NA
-
Prognostic Value of MRD Detection in CA125 Non-sensitive Ovarian Cancer Patients
NCT06182917 ·Status: RECRUITING
-
Evaluation and Implementation of New Biomarkers and Algorithms for Diagnosis of Ovarian Cysts/Tumors in the Pelvis
NCT03193671 ·Status: COMPLETED
-
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
NCT01139957 ·Status: COMPLETED
-
Retrospective Case Study to Validate Existing Chemoresponse Marker Test in Ovarian, Peritoneal or Fallopian Cancer Cases
NCT01048814 ·Status: COMPLETED
-
Early Detection of Relapse in Ovarian Cancer Using Capillary Home-sampling and a Protein Biomarker Test
NCT06445621 ·Status: RECRUITING
-
Biomarkers in Patients With Previously Untreated Invasive Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT01295489 ·Status: COMPLETED
-
Ovarian Screening Study
NCT00267072 ·Status: COMPLETED
-
Lavage of the Uterine Cavity for Diagnosis of Ovarian Cancer
NCT03606486 ·Status: TERMINATED ·Phase: NA
-
CA-125 in Screening Patients at High Risk for Ovarian Cancer
NCT00080639 ·Status: WITHDRAWN
-
Study of Tumor Tissue Samples From Patients Who Have Undergone Surgery for Advanced Stage III or Stage IV Ovarian Epithelial Cancer
NCT01000259 ·Status: RECRUITING
-
Use of New MolEcular MarkErs for a persoNalized Therapy in Ovarian Cancer-MEMENTO
NCT06917469 ·Status: COMPLETED
-
Early Detection of Ovarian Cancer: GC/FT-ICR Mass Spectrometry and Canine Olfaction
NCT00757952 ·Status: COMPLETED
-
Collection of Tissue Samples From Patients With Stage III or Stage IV Ovarian Epithelial Cancer
NCT01096394 ·Status: COMPLETED
-
HE4 as a Relapse Biomarker in Ovarian Cancers
NCT02595281 ·Status: COMPLETED ·Phase: NA
-
Tivozanib As Maintenance Therapy In GYN
NCT01972516 ·Status: TERMINATED ·Phase: PHASE2
-
EC17 for Intraoperative Imaging in Occult Ovarian Cancer
NCT02000778 ·Status: COMPLETED ·Phase: PHASE1
-
Carboplatin and Paclitaxel With or Without Bevacizumab Compared to Docetaxel, Carboplatin, and Paclitaxel in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Carcinoma (Cancer)
NCT00085358 ·Status: COMPLETED ·Phase: PHASE1
-
DOD Long-Term Survivors of Ovarian Cancer
NCT02321735 ·Status: UNKNOWN ·Phase: NA
-
Healthy Volunteers Study
NCT06962059 ·Status: RECRUITING
-
A Prospective Multicenter Diagnostic Biomarker Study to Discriminate Borderline From Stage I Invasive Ovarian Cancer
NCT06709872 ·Status: RECRUITING